Bausch Health Companies Inc (BHC) Given Consensus Rating of “Hold” by Brokerages
Shares of Bausch Health Companies Inc (NYSE:BHC) have received an average recommendation of “Hold” from the seventeen brokerages that are covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $28.20.
A number of equities analysts have recently commented on the stock. ValuEngine raised shares of Bausch Health Companies from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. Bank of America reissued an “underperform” rating and issued a $18.00 price target on shares of Bausch Health Companies in a research report on Wednesday, March 20th. SunTrust Banks started coverage on shares of Bausch Health Companies in a research report on Tuesday, March 19th. They set a “buy” rating and a $30.00 target price on the stock. Zacks Investment Research lowered shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Friday, February 15th. Finally, Mizuho boosted their target price on shares of Bausch Health Companies from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th.
Shares of NYSE:BHC traded up $0.46 during trading on Tuesday, reaching $20.98. The stock had a trading volume of 57,640 shares, compared to its average volume of 4,602,441. Bausch Health Companies has a 52 week low of $17.20 and a 52 week high of $28.45. The firm has a market cap of $7.36 billion, a price-to-earnings ratio of 5.23, a P/E/G ratio of 0.47 and a beta of 0.61. The company has a quick ratio of 0.83, a current ratio of 1.08 and a debt-to-equity ratio of 8.61.
A number of hedge funds have recently made changes to their positions in BHC. FIL Ltd increased its holdings in Bausch Health Companies by 69.6% in the 1st quarter. FIL Ltd now owns 10,545,300 shares of the company’s stock valued at $260,170,000 after buying an additional 4,327,851 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Bausch Health Companies by 0.9% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 8,452,664 shares of the company’s stock valued at $156,267,000 after buying an additional 75,175 shares during the period. Bank of Montreal Can increased its holdings in Bausch Health Companies by 28.2% in the 1st quarter. Bank of Montreal Can now owns 3,702,077 shares of the company’s stock valued at $91,441,000 after buying an additional 815,311 shares during the period. Orbimed Advisors LLC increased its holdings in Bausch Health Companies by 89.1% in the 4th quarter. Orbimed Advisors LLC now owns 3,600,300 shares of the company’s stock valued at $66,498,000 after buying an additional 1,696,400 shares during the period. Finally, Norges Bank bought a new stake in Bausch Health Companies in the 4th quarter valued at $59,054,000. 53.67% of the stock is currently owned by institutional investors and hedge funds.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Read More: How to trade on quiet period expirations
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.